L-BAIBA,
does it really help with Increased metabolic rate and reduced body fat?
research showsIn the first published direct randomized trial, 500 mg/day of MitoBurn for 56 days did not improve resting metabolic rate, body weight, DXA fat mass, or body-fat percentage versus placebo. Cellular and rodent fat-browning mechanisms and observational associations involving circulating BAIBA do not establish supplement efficacy, supporting D.
ads claimMarketing describes an exercise mimetic, brown-fat switch, or metabolism booster, translating preclinical mechanisms into actual fat loss. The direct human trial did not confirm that translation.
Useful facts when choosing a product
- MitoBurn raw material and finished products appear in Korean ingredient catalogs and cross-border retail channels; one example contains 500 mg per capsule.
- The direct human trial used 500 mg/day for 56 days.
- L-BAIBA and D-BAIBA are different enantiomers, so general BAIBA research cannot all be transferred to an L-BAIBA product.
- Long-term high-dose safety and safety in pregnancy, lactation, chronic disease, and medication use are not established.
What the research actually shows
The 2026 Allen trial assigned adults following calorie restriction and exercise to placebo (12), L-BAIBA (13), or L-BAIBA plus grains of paradise (12). L-BAIBA alone at 500 mg/day for 56 days produced no group-by-time difference in resting metabolic rate, weight, DXA fat mass, or body-fat percentage. The 2014 Roberts study found fat browning and hepatic fatty-acid oxidation in cellular and animal models and human observational associations; it was not a supplementation trial.
Why this is classified as D (25)
A direct human trial exists, so the grade is not ?. Its null results for metabolism, weight, and body fat support D with 25 points. Sponsorship and small size limit certainty but do not establish efficacy.
Counterpoint. Lower subjective hunger warrants follow-up but is not equivalent to lower energy intake, weight, or body fat.
Rejudgment record. New verdict — A direct trial of MitoBurn at 500 mg/day was null for resting metabolic rate, weight, and DXA body fat; preclinical mechanisms and observational correlations were not treated as supplementation efficacy
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Increased resting metabolic rate | D | A direct trial of MitoBurn at 500 mg/day was null versus placebo. |
| Reduced body weight and body fat | D | Body weight, DXA fat mass, and body-fat percentage all showed no between-group benefit. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Allen LE et al. 2026 | Randomized double-blind placebo-controlled trial | n=37 | Funded by NNB Nutrition; senior author was a paid adviser | Resting metabolic rate, weight, DXA body fat, and appetite visual analog scales | Null for metabolism, weight, fat mass, and body-fat percentage; only hunger ratings decreased. | Key |
| Roberts LD et al. 2014 | Cellular and animal experiments plus human observational analysis | Public and academic funding | Fat browning, hepatic fatty-acid oxidation, and circulating BAIBA associations | Reported preclinical mechanisms and human correlations, but did not test oral L-BAIBA efficacy. | Mechanistic context |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-18 · Corrections: none
Cite this verdict
[Chamgap] L-BAIBA (MitoBurn) x increased metabolic rate and reduced body fat — Evidence Grade D·25. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/weight/l-baiba-metabolic-rate-body-fat/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.